RxDoctor Payments Data

Sharad Dass, MD

Critical Care Medicine · San Jose, CANPI 1144312125

Payments from drug & device makers

$17,745in general payments, 2019–2025

Across 100 payments — averaging $177.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$12K
  • Veran Medical Technologies, Inc.$819
  • GSK$670
  • AstraZeneca$665
  • Novo Nordisk$477
  • Boehringer Ingelheim$299
  • plus $3K from 21 others

What the payments were for

  • Speaking & faculty fees$3,00017%
  • Travel & lodging$6654%
  • Food & beverage$5,02128%
  • Education$9,05951%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,745 in reported general payments places this provider in the 90th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$483,739
Medicare patients
445
Services billed
4,648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter168$135,556
Breo ElliptaFluticasone/Vilanterol65$26,832
Spiriva HandihalerTiotropium Bromide24$18,629
Lacosamide11$11,057
Incruse ElliptaUmeclidinium Bromide15$9,219
Spiriva RespimatTiotropium Bromide15$8,654
EliquisApixaban27$7,703
Pantoprazole Sodium23$5,945
Semglee (Yfgn)Insulin Glargine-Yfgn17$5,083
Rifabutin14$5,078
Potassium Chloride30$4,652
RenacidinCitric Ac/Gluconolact/Mag Carb18$3,080
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$2,759
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate77$2,667
SymbicortBudesonide/Formoterol Fumarate11$2,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$670$171,607248 claims
Boehringer IngelheimSpiriva Respimat$299$8,65415 claims
AstraZenecaSymbicort$665$2,61511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 715 critical care medicine providers in California.

Other critical care medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →